20.06.2024 14:55:03 - dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Gilead Sciences 885823 NASDAQ 77,010 26.07.24 22:00:11 +0,500 +0,65% 77,030 77,050 76,030 76,510

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH